Background And Aim: The risk of acquiring hepatitis B virus (HBV) infection through exposure to blood or its products is highest amongst health care workers (HCWs). Despite potential risks, a proportion of HCWs never get vaccinated. India is second to China in the numbers of people with chronic HBV. This study aimed to investigate the vaccination practices and the prevalence of HBV infection in HCWs in India.
Methods: A total of 2162 HCWs were screened for the presence of serological markers of HBV and hepatitis C virus (HCV). Occult HBV infection was tested by detection of HBV-DNA for surface and core regions by nested polymerase chain reaction in HBsAg-negative and IgG anti-hepatitis core antigen-positive subjects.
Results: Only 1198 (55.4%) of the 2162 HCWs screened had been vaccinated; and 964 (44.6%) were not vaccination-status conscious; of these HCWs, 600 (27.7%) had never been vaccinated and 364 (16.4%) were unaware of their vaccination status. Protective (> 10 IU/mL) anti-hepatitis B surface (anti-HBs) antigen titers were seen in only 61.7%. The anti-HBs titers were found to be lower with the passage of time; the median anti-HBs titers in subjects who were vaccinated > 10 years ago were significantly lower than those who had been vaccinated < 5 years ago (P < 0.001). One percent of HCWs were HBsAg-positive, and 24.7% of 700 HCWs screened had past exposure (IgG-anti-HBc-positive). Occult HBV was detected in 5% of 120 positive subjects with past exposure; all had anti-HBs titers > 10 IU/mL.
Conclusions: Even today, 28% HCWs in India are unvaccinated and 17% are unaware of their vaccination status. This data suggests that use of hepatitis B immune globulin be mandatory in needle-pricked HCWs in India, and that implementation of awareness strategies is urgent. Since the anti-HBs titers decline in a fair proportion, there is justification for giving a booster dose of vaccine 10 years after primary vaccination to HCWs in India.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1440-1746.2008.05483.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protected or not? Hepatitis B vaccination status among healthcare workers and the level of protection post-vaccination.
Med J Armed Forces India
December 2024
Commanding Officer, 324 Field Hospital, C/o 56 APO, India.
Background: Hepatitis B virus infection is one of the major concerns in global health care. With a far-reaching health, social, economic impact, preventive strategies form the cornerstone of its management. Knowledge about vaccination status and protection rendered thereof would aid in more wholesome management among highrisk population groups like healthcare workers.
View Article and Find Full Text PDFPrevalence of hepatitis B surface antibody among previously vaccinated healthcare workers in Tashkent, Uzbekistan.
Hum Vaccin Immunother
December 2024
Central Asia Field Epidemiology Training Program, Almaty, Kazakhstan.
Healthcare workers (HCW) have high occupational risk for hepatitis B and Uzbekistan held two HCW vaccination campaigns in 2015 and 2022. Hepatitis B antibody testing (anti-HBs) after Hepatitis B (HepB) vaccination is recommended by the U.S.
View Article and Find Full Text PDFEfficacy of HBV booster dose administration in Italian medical students in relation to health determinants.
Hum Vaccin Immunother
December 2024
Department of Life, Health and Environmental Science, University of L'Aquila, L'Aquila, Italy.
Article Synopsis
- The study assessed the effectiveness of a booster HBV vaccine in Italian medical students, revealing that a significant portion had low antibody levels after 15 years.
- Out of 625 students, 355 were given a booster, and 92.77% of those who received it achieved adequate antibody levels after one month.
- Results showed that physical activity improved immune response to the booster, highlighting the importance of maintaining higher pre-booster antibody levels for better vaccine effectiveness.
Immune response to GeneVac-B (rDNA I.P. hepatitis B vaccine) in vaccinated persons with a standard schedule in Bobo-Dioulasso, Burkina Faso.
IJID Reg
December 2024
Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaire (LR-MIP), Institut de Recherche en Science de la Santé, Ouagadougou, Burkina Faso.
Objective: This study aimed to evaluate the immune response in people fully vaccinated against hepatitis B with the GeneVac-B vaccine in Burkina Faso under actual conditions of use.
Methods: This cross-sectional study included individuals fully vaccinated with GeneVac-B. For each consenting participant, sociodemographic and clinical data were collected using a structured questionnaire.
A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs titers.
Vaccine
January 2025
VBI Vaccines Inc, Cambridge, MA, USA. Electronic address:
Article Synopsis
- PreHevbrio® is a 3-antigen hepatitis B virus (HBV) vaccine designed to produce three types of HBV envelope proteins, leading to a more robust immune response compared to traditional single-antigen vaccines.
- The study found that the increased immunogenicity of the 3-antigen vaccine is not linked to glycosylation, but rather to its ability to trigger T cell responses specific to the PreS antigens.
- Results show that the 3-antigen vaccine generates stronger and longer-lasting antibody responses, correlating significantly with T cell activity and better antibody production.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!